Research Analysts Offer Predictions for TEVA Q3 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Equities researchers at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a report released on Monday, November 4th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.67 per share for the quarter, up from their prior forecast of $0.66. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.33 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ FY2025 earnings at $2.55 EPS and Q2 2026 earnings at $0.61 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.04. The business had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.08 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%.

Other analysts also recently issued research reports about the stock. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Trading Up 0.4 %

Shares of Teva Pharmaceutical Industries stock opened at $17.50 on Wednesday. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The firm has a 50-day moving average of $17.98 and a 200-day moving average of $17.07. Teva Pharmaceutical Industries has a 52-week low of $8.55 and a 52-week high of $19.31. The stock has a market cap of $19.83 billion, a PE ratio of -44.87, a PEG ratio of 1.34 and a beta of 0.87.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its position in Teva Pharmaceutical Industries by 26.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 36,753 shares of the company’s stock worth $519,000 after purchasing an additional 7,763 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 1.3% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,159,333 shares of the company’s stock worth $30,468,000 after buying an additional 27,713 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Teva Pharmaceutical Industries by 3.0% in the 1st quarter. Nordea Investment Management AB now owns 91,837 shares of the company’s stock valued at $1,299,000 after acquiring an additional 2,701 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 3.7% during the 1st quarter. Daiwa Securities Group Inc. now owns 115,693 shares of the company’s stock valued at $1,632,000 after acquiring an additional 4,170 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Teva Pharmaceutical Industries during the 1st quarter worth $93,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.